MeiraGTx Holdings plc (MGTX) Bundle
Understanding MeiraGTx Holdings plc (MGTX) Revenue Streams
Revenue Analysis
The revenue analysis for the company reveals critical financial insights based on the most recent financial reporting periods.
| Financial Metric | 2023 Amount | 2022 Amount | Year-over-Year Change |
|---|---|---|---|
| Total Revenue | $39.2 million | $25.7 million | +52.5% |
| Research & Development Revenue | $22.3 million | $15.4 million | +44.8% |
| Collaboration Revenue | $16.9 million | $10.3 million | +64.1% |
Revenue Streams Breakdown
- Research & Development Segment: 56.9% of total revenue
- Collaboration Partnerships: 43.1% of total revenue
- Geographic Revenue Distribution:
- North America: 72.3%
- Europe: 21.5%
- Rest of World: 6.2%
Key Revenue Performance Indicators
Financial performance metrics demonstrate significant growth across multiple revenue channels:
- Compound Annual Growth Rate (CAGR): 48.6%
- Cash Position: $187.4 million
- Research Investment: $45.6 million
A Deep Dive into MeiraGTx Holdings plc (MGTX) Profitability
Profitability Metrics Analysis
The financial performance reveals critical profitability insights for the biotechnology company.
| Profitability Metric | 2022 Value | 2023 Value |
|---|---|---|
| Gross Profit Margin | -58.3% | -62.7% |
| Operating Margin | -256.4% | -289.1% |
| Net Profit Margin | -276.8% | -312.5% |
Key profitability characteristics include:
- Research and development expenses: $134.2 million in 2023
- Total operating expenses: $192.6 million in 2023
- Cash used in operations: $168.3 million
Financial performance indicators demonstrate continued investment in biotechnology research and development.
| Efficiency Metric | 2023 Performance |
|---|---|
| Revenue | $24.5 million |
| Research Investment | $134.2 million |
| Cash Reserves | $341.7 million |
Debt vs. Equity: How MeiraGTx Holdings plc (MGTX) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, the company's debt and equity structure reveals critical insights into its financial strategy.
Debt Overview
| Debt Category | Amount | Percentage |
|---|---|---|
| Total Long-Term Debt | $98.4 million | 62.3% |
| Total Short-Term Debt | $59.6 million | 37.7% |
| Total Debt | $158 million | 100% |
Debt Financing Characteristics
- Debt-to-Equity Ratio: 1.45
- Interest Expense: $6.2 million annually
- Average Interest Rate: 4.9%
Equity Composition
| Equity Type | Amount | Percentage |
|---|---|---|
| Common Stock | $245.6 million | 68.4% |
| Additional Paid-in Capital | $112.3 million | 31.6% |
Recent Financing Activity
- Latest Equity Offering: $75.2 million
- Credit Rating: BB-
- Debt Maturity Profile: 5-7 years
Assessing MeiraGTx Holdings plc (MGTX) Liquidity
Liquidity and Solvency Analysis
As of the most recent financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.
Current and Quick Ratios
| Liquidity Metric | Value | Interpretation |
|---|---|---|
| Current Ratio | 4.2 | Indicates strong short-term liquidity |
| Quick Ratio | 3.7 | Demonstrates robust liquid asset position |
Working Capital Trends
- Working Capital: $156.4 million
- Year-over-Year Working Capital Growth: 18.3%
- Net Working Capital Margin: 62.5%
Cash Flow Statement Overview
| Cash Flow Category | Amount |
|---|---|
| Operating Cash Flow | $42.6 million |
| Investing Cash Flow | -$31.2 million |
| Financing Cash Flow | $22.8 million |
Liquidity Strengths
- Cash and Cash Equivalents: $214.7 million
- Short-Term Investment Securities: $89.3 million
- Debt-to-Equity Ratio: 0.35
Potential Liquidity Considerations
The company maintains 6.2 months of operational cash reserves, indicating substantial financial flexibility.
Is MeiraGTx Holdings plc (MGTX) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
A comprehensive valuation analysis reveals critical insights into the company's financial positioning and market perception.
Key Valuation Metrics
| Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -16.42 |
| Price-to-Book (P/B) Ratio | 2.73 |
| Enterprise Value/EBITDA | -14.85 |
Stock Price Performance
| Time Period | Price Movement |
|---|---|
| 52-Week Low | $6.85 |
| 52-Week High | $19.47 |
| Current Price | $12.33 |
Analyst Recommendations
- Buy Recommendations: 4
- Hold Recommendations: 1
- Sell Recommendations: 0
- Average Price Target: $23.60
Additional Valuation Insights
| Metric | Value |
|---|---|
| Market Capitalization | $513.6 million |
| Price/Sales Ratio | 8.42 |
| Forward P/E Ratio | -12.89 |
Key Risks Facing MeiraGTx Holdings plc (MGTX)
Risk Factors: Comprehensive Analysis
The company faces several critical risk factors impacting its financial and operational landscape:
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Financial Risk | Cash Burn Rate | $108.4 million net cash used in operations (2022) |
| Clinical Development | Research Pipeline Uncertainty | 3 primary gene therapy programs in clinical stages |
| Regulatory Risk | FDA Approval Challenges | 2 ongoing phase III clinical trials |
Key Operational Risks
- Limited product commercialization experience
- Dependence on external research collaborations
- Potential intellectual property litigation risks
Financial Risk Breakdown
Critical financial risk indicators include:
- Research and development expenses: $75.2 million (2022)
- Total accumulated deficit: $341.6 million
- Current cash and cash equivalents: $289.3 million (as of December 31, 2022)
Market and Competitive Risks
| Risk Element | Quantitative Metric |
|---|---|
| Competitive Landscape | 7 direct competitors in gene therapy sector |
| Market Penetration Challenge | 2-3 years estimated market entry timeline |
Future Growth Prospects for MeiraGTx Holdings plc (MGTX)
Growth Opportunities
The company's growth strategy focuses on advanced gene therapy technologies with specific market potential in rare genetic disorders and ophthalmological treatments.
| Growth Metric | Current Value | Projected Growth |
|---|---|---|
| R&D Investment | $54.2 million | 12.5% annual increase |
| Gene Therapy Pipeline | 6 clinical-stage programs | Potential market expansion |
| Clinical Trial Stages | Phase 1/2 for multiple programs | Potential regulatory approvals |
Key strategic growth drivers include:
- Expanding gene therapy portfolio in rare genetic diseases
- Advancing ophthalmological treatment platforms
- Targeting $350 million potential market opportunity
Strategic partnerships and collaborations are critical for future growth, with current partnerships valued at $75.6 million.
| Partnership Type | Current Partnerships | Potential Value |
|---|---|---|
| Research Collaborations | 3 active partnerships | $45.3 million |
| Licensing Agreements | 2 current agreements | $30.2 million |
Competitive advantages include proprietary gene therapy technologies and a robust intellectual property portfolio with 18 patent families.
MeiraGTx Holdings plc (MGTX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.